Martín Pérez-Leal

Dr. Martín Pérez-Leal

Universidad Europea de Valencia
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
CECristina Estornut
Cristina Estornut
GRGiulia Rinaldi
Giulia Rinaldi
MCMaría Carmen Carceller
María Carmen Carceller
SESergio Estornut
Sergio Estornut
MPMartín Pérez-Leal
Martín Pérez-Leal

Verified
Journal Article
Open access
PDF file
PMPaula Montero
Paula Montero
JMJavier Milara
Javier Milara
MPMartín Pérez-Leal
Martín Pérez-Leal
CECristina Estornut
Cristina Estornut
ILInés Roger Laparra
Inés Roger Laparra
JCJulio Cortijo
Julio Cortijo
Paclitaxel is a microtubule-stabilizing chemotherapeutic agent approved for the treatment of ovarian, non-small cell lung, head, neck, and breast cancers. Despite its beneficial effects on cancer and widespread use, paclitaxel also damages healthy tissues, including the skin. However, the mechanisms that drive these skin adverse events are not clearly understood. In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1α, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC). Some of the mechanisms driving these adverse skin events in vitro are mediated by the activation of toll-like receptor 4 (TLR-4), which phosphorylate transcription of nuclear factor kappa B (NF-κb). This is the first study analyzing paclitaxel effects on healthy human epidermal cells with an epidermis 3D model, and will help in understanding paclitaxel’s effects on the skin.

23 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
PMPaula Montero
Paula Montero
MPMartín Pérez-Leal
Martín Pérez-Leal
JPJose Alejandro Pérez-Fidalgo
Jose Alejandro Pérez-Fidalgo
CSCelia Sanz
Celia Sanz
CECristina Estornut
Cristina Estornut
JCJulio Cortijo
Julio Cortijo
Background: Paclitaxel is a microtubule-stabilizing chemotherapeutic agent. Despite its widespread use, it damages healthy tissues such as skin. The goal of this study was to prove that the real impact of paclitaxel-induced skin toxicity could be underestimated because the adverse events might appear asymptomatic. Methods: Gynecological cancer patients were recruited. Skin parameters measurements were taken after three and six paclitaxel cycles. Measurements were conducted using specific probes which measure hydration, transepidermal water loss (TEWL), sebum, elasticity and firmness, erythema, roughness, smoothness, skin thickness, and desquamation levels. Further, a 3D epidermis model was incubated with paclitaxel to analyze gene and protein expression of aquaporin 3, collagen type 1, elastin, and fibronectin. Results: Paclitaxel induced alterations in the skin parameters with no visible clinical manifestations. Gynecological cancer patients under paclitaxel treatment had a decrease in hydration, TEWL, sebum, elasticity, and thickness of the skin, while erythema, roughness, and desquamation were increased. The molecular markers, related to hydration and the support of the skin layers, and analyzed in the 3D epidermis model, were decreased. Conclusions: Results suggest that paclitaxel modifies gene and protein expression of skin-related molecular markers, and impairs different physical, physiological, and biomechanical properties of the skin of cancer patients at a subclinical level.

28 December 2023 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
MPMartín Pérez-Leal
Martín Pérez-Leal
FLFederico Lanciano
Federico Lanciano
NFNicla Flacco
Nicla Flacco
CECristina Estornut
Cristina Estornut
MCMaría Carmen Carceller
María Carmen Carceller

5 March 2025 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
MPMartín Pérez-Leal
Martín Pérez-Leal
BHBouchra El Helou
Bouchra El Helou
ILInés Roger Laparra
Inés Roger Laparra

28 November 2025 in International Endodontic Journal
Verified
Journal Article
Closed access
GSGermán Sánchez‐Herrera
Germán Sánchez‐Herrera
FAFernando José Alfaro‐Ochoa
Fernando José Alfaro‐Ochoa
ESEstefanía Sayas‐Balaguer
Estefanía Sayas‐Balaguer
MPMartín Pérez-Leal
Martín Pérez-Leal
CPCristina Palma‐Carrió
Cristina Palma‐Carrió
NFNicla Flacco
Nicla Flacco